228) nt-facing apps supporting promote chronic disease management. |
229) ing, informed patient, collaboration, and disease management. |
230) ss the quality of mobile apps for chronic disease management. |
231) at can aid in tumor monitoring throughout disease management. |
232) ls paralleled several indices of COVID-19 disease severity (e.g., kidney dysfunction |
233) ailable noninvasive markers for assessing disease severity and mortality risk in pul |
234) standing of host determinants that impact disease severity and offer potential thera |
235) ffer from high-intensity inflammation and disease severity than the female populatio |
236) itis severity, we asked if Ket/Xyl affect disease severity. |
237) contracting COVID-19, taking into account disease severity. |
238) Background: Parkinson's Disease (PD) is a chronic neurodegenerativ |
239) ials in five individuals with Parkinson's disease (PD) for up to 15 months after imp |
240) Parkinson's disease (PD) is a significant cause of dis |
241) Parkinson's disease (PD) is a significant cause of dis |
242) entified correlations between Parkinson's disease (PD) risk and lifestyle factors. |
243) understand the role of gut microbiota in disease pathogenesis and therapeutic targe |
244) revealed or supported key discoveries in disease pathogenesis and therapy developme |
245) These factors seem to contribute to disease pathogenesis before the onset of c |
246) nding the mechanism underlying SARS-CoV-2 disease pathogenesis remains crucial for t |
247) rs in development, brain homeostasis, and disease pathogenesis. |
248) SLE patients with high disease activity had increased concentrati |
249) use of pregnancy registers and validated disease activity measurement tools for pre |
250) = 0.007) compared with those with lower disease activity. |
251) possible role for EBV reactivation in SLE disease activity. |
252) with traits that confer resistance to the disease are needed. |
253) breast cancer and diagnosis of metastatic disease are possible, and are expected to |
254) affect many organ systems, lung and heart disease are the leading causes of death. |
255) mal defects, respiratory failure and lung disease are the leading causes of morbidit |
256) are thought to influence cardiometabolic disease development and individuals' diets |
257) that could potentially be used to predict disease development. |
258) isk of future diabetes and cardiovascular disease development. |
259) ody space-type IR-associated degenerative disease development. |
260) selective pressures related to infectious disease or an undefined role in primate ph |
|